Core Insights - Zynex, Inc. reported lower than expected revenue for the fourth quarter and full year ended December 31, 2024, primarily due to slower payments from certain payers and a temporary suspension of payments by Tricare as they review prior claims [1] Company Summary - Zynex, Inc. is currently under investigation by Holzer & Holzer, LLC to determine if the company complied with federal securities laws following the disappointing financial results announcement [1] - The announcement of the revenue shortfall led to a decline in Zynex's stock price [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

The mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companies, offering the Seeking Alpha investor compelling points of view on these often overlooked investment opportunities; and periodically identifying potential opportunities in large- and mega-cap companies, expanding the scope to provide encompassing coverage ...

Financial Data and Key Metrics Changes - Net revenue for Q4 2024 was $46 million, a decrease from $47.3 million in Q4 2023 [33] - Device revenue decreased to $14.8 million from $16.3 million year-over-year, while supplies revenue increased slightly to $31.2 million from $31 million [33] - Gross profit remained stable at $36 million, representing 78% of revenue, consistent with the previous year [34] - Net loss for Q4 2024 was $615,000, compared to a net income of $1.2 million in Q4 2023 [35] - Adjusted EBITDA fell to $584,000 from $9.9 million in the same quarter last year [35] Business Line Data and Key Metrics Changes - Revenue increased by 4% in 2024, with order growth at 16% [24] - Average revenue per sales representative increased by 22% to $490,000 in 2024, despite a reduction in the total number of sales representatives from approximately 475 to 330 [24] Market Data and Key Metrics Changes - The patient monitoring business is expected to enter a multi-billion dollar market with the anticipated FDA clearance of the NiCO pulse oximeter [32] - The company is optimistic about capturing identified sales opportunities within its designated sales territories, estimated at $800 million [13] Company Strategy and Development Direction - The company is diversifying its revenue streams by adding new products, including private label products in bracing and compression [7] - Focus on expanding the sales force to new prescribers, including national workers' compensation chains and the VA [7] - The company aims to maintain a long-term growth vision despite short-term disruptions, emphasizing the importance of product diversification [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term prospects of the company, despite challenges related to Tricare's temporary payment suspension [12][37] - The company is restructuring to optimize its cost structure and has implemented measures to ensure long-term growth and profitability [11][15] - Revenue guidance for 2025 remains uncertain due to the lack of visibility surrounding Tricare payments, with an anticipated Q1 revenue of approximately $30 million [39] Other Important Information - Tricare's temporary suspension of payments could significantly impact revenue, as it represents 20% to 25% of total revenue [19] - The company is undergoing a staff reduction of 15%, primarily affecting corporate office employees, which is expected to result in annual savings of approximately $35 million [23] Q&A Session Summary Question: What was accomplished in the fourth quarter regarding staff reductions? - The company achieved about $30 million in annual savings, with less than half realized in 2024, and expects further reductions in sales and G&A expenses [46][47] Question: What is the commercial path to market for the NiCO pulse oximeter? - The strategy includes direct sales, partnerships with distributors, and an indirect sales force to penetrate the market upon FDA clearance [52][54] Question: What was the nature of the 2022 audit by Tricare? - The audit was a routine post-payment audit with standard adjustments suggested, and no major issues were identified [58] Question: Why is there a lack of visibility into sales for 2025? - The uncertainty is primarily due to Tricare's significant role in revenue, and the company is cautious about providing guidance until more clarity is obtained [61] Question: What is the plan for the upcoming meeting with Tricare? - The company will present data from the 2022 audit and highlight compliance with previous adjustments during the appeal meeting [64] Question: Could other payers follow Tricare's lead in reviewing claims? - Management does not foresee a connection between Tricare's actions and other payers, emphasizing that each operates independently [70]

NASDAQ: ZYXI Investor Presentation July 2024 Forward Looking Statement This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated ev ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

ENGLEWOOD, Colo., March 11, 2025 -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update Management Commentary "In the fourth quarter of 2024 we continued our steady growth in orders and delivered another year of ...

Core Insights - Zynex, Inc. reported steady growth in orders and profitability for 2024, despite a revenue shortfall in Q4 due to delayed payments from certain payers, particularly Tricare, which accounts for 20-25% of annual revenue [2][3][4] - The company is restructuring its workforce, reducing staff by approximately 15% to align with current revenue, which is expected to save around $35 million annually [4][5] - Zynex completed a successful clinical trial for its NiCO laser pulse oximeter, which utilizes advanced laser technology for more accurate blood oxygenation measurements [6] Financial Performance - Q4 2024 net revenue was $46.0 million, down from $47.3 million in Q4 2023, with a gross profit of $36.0 million, maintaining a gross margin of 78% [8] - For the full year 2024, net revenue increased by 4% to $192.4 million, with a gross profit of $152.9 million, representing 80% of revenue [12] - The company reported a net loss of $0.6 million in Q4 2024, compared to a net income of $1.2 million in Q4 2023, and an adjusted EBITDA of $0.6 million, down from $9.9 million in the prior year [10][12] Operational Updates - The company is focusing on payer expansion to mitigate near-term revenue challenges, with expectations for results to materialize in 2025 [5] - Zynex has maintained a healthy balance sheet, having repurchased over $80 million in shares, enhancing shareholder value [7] - The company anticipates Q1 2025 net revenue of at least $30 million, with a projected loss per share of ($0.30) or better, expecting revenue growth throughout the year [15]

Core Viewpoint - Zynex, Inc. will hold a conference call to discuss its financial results for Q4 and the full year of 2024 on March 11, 2025, at 4:15 PM Eastern Time [1] Group 1: Conference Call Details - The conference call will include a question and answer session following the management's presentation [2] - Dial-in numbers for the call are provided for both U.S. & Canada and international participants [2] - A webcast link will be available for those who wish to stream the call online [2] Group 2: Company Overview - Zynex, Inc. specializes in the development, manufacturing, marketing, and sale of non-invasive medical devices for pain management and rehabilitation [3] - The company also produces monitoring systems for fluid, sepsis, and laser-based pulse oximetry for hospital use [3] - Founded in 1996, Zynex has established itself in the medical technology sector [3]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive has a strong emphasis on technology adoption to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]